Elucidate the genomic, immunogenic, and proteomic aberrations that serve as molecular drivers for a wide variety of solid tumors and mandate the necessity for a personalized approach to treatment
|
|
|
|
|
Select personalized treatments for patients with breast, gastrointestinal, genitourinary, and lung cancer based on the characteristics of each patient and the molecular profile of each tumor
|
|
|
|
|
Assess treatments currently in late-phase development that are being studied for their ability to address actionable molecular targets common to disease state subsets within breast, gastrointestinal, genitourinary, and lung cancers
|
|
|
|
|